Trial Profile
A Phase III Multicenter Randomized Study of the Biological and Clinical Efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients With Low CD4+ Counts Under Active Antiretroviral Therapy (SILCAAT Amendment 4)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Antiretrovirals
- Indications HIV infections; HIV-1 infections
- Focus Therapeutic Use
- Acronyms SILCAAT
- 10 Dec 2010 Additional lead trial centre, investigator and trial location (USA) identified as reported by ClinicalTrials.gov.
- 10 Dec 2010 Additional lead trial centre, investigator and trial location (USA) identified as reported by ClinicalTrials.gov.
- 15 Oct 2009 Results were published in the New England Journal of Medicine.